Last reviewed · How we verify

ALX-0061 — Competitive Intelligence Brief

ALX-0061 (ALX-0061) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-17 inhibitor. Area: Immunology.

phase 2 IL-17 inhibitor IL-17A, IL-17F Immunology Biologic Live · refreshed every 30 min

Target snapshot

ALX-0061 (ALX-0061) — Ablynx, a Sanofi company. ALX-0061 is a nanobody targeting IL-17A and IL-17F, which are pro-inflammatory cytokines involved in autoimmune diseases.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ALX-0061 TARGET ALX-0061 Ablynx, a Sanofi company phase 2 IL-17 inhibitor IL-17A, IL-17F

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-17 inhibitor class)

  1. Ablynx, a Sanofi company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALX-0061 — Competitive Intelligence Brief. https://druglandscape.com/ci/alx-0061. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: